Sai Life Sciences Limited is coming up with an IPO consisting of a fresh issue of 1.73 crore shares worth INR 950 crores and an offer to sell 3.81 crore existing shares worth INR 2,092.62 crores. The company aims to repay borrowings partially or fully and fund general corporate purposes.
Sai Life Sciences IPO – Important Dates
| Sai Life Sciences Limited IPO Date | December 11, 2024 to December 13, 2024 |
| Sai Life Sciences Limited IPO Listing Date | December 18, 2024 |
| Sai Life Sciences Limited IPO Price | INR 522-549 per share |
| Sai Life Sciences Limited IPO Lot Size | 27 Shares |
| Sai Life Sciences Limited IPO Total Issue Size | INR 3,042.62 crores |
| Sai Life Sciences Limited IPO Basis of Allotment | December 16, 2024 |
| Sai Life Sciences Limited IPO Initiation of Refunds | December 17, 2024 |
| Sai Life Sciences Limited IPO Credit of Shares to Demat | December 17, 2024 |
| Sai Life Sciences Limited IPO Issue Type | Book Built Issue IPO |
| Sai Life Sciences Limited IPO Listing At | BSE NSE |
Sai Life Sciences Limited IPO – Company Profile
Sai Life Sciences Limited, a leading CRDMO, provides end-to-end drug discovery, development, and manufacturing services to global pharmaceutical innovators. It has advanced facilities in India and research hubs near US and UK innovation centres.
With globally accredited facilities and 2,353 scientific staff, including 302 PhDs, the company specialises in high-volume and intricate drug development manufacturing, supported by USFDA and PMDA approvals and flexible production setups.
Committed to sustainability, the company upholds high HSE standards, implements energy-saving measures, boosts renewable energy usage, reduces emissions, and achieves PSCI membership and EcoVadis silver rating for its ESG initiatives.
Sai Life Sciences Ltd IPO Fundamental Analysis
Sai Life Sciences Limited’s financial analysis reveals a mixed performance. Revenue has steadily grown, accompanied by increased equity, profitability, EPS, RoNW, and total assets, highlighting the company’s strong financial growth and expansion potential.
- Revenue Trend: The revenue increased from ₹8,695.93 millions in March 2022 to ₹12,171.39 millions in March 2023. The revenue for the current year’s 6-month period ending September 2024 is INR 6,752.85 million.
- Equity and Liabilities: Both equities and liabilities have shown a consistent increase over the periods, reflecting potential growth and expansion.
- Profitability: The profit after tax (PAT) has significantly increased from ₹62.26 million in March 2022 to ₹280.12 million by September 2024. This improvement in profitability could be a source of confidence among investors.
- Earnings per Share (EPS): The diluted EPS has risen from ₹0.34 in March 2022 to ₹1.49 by September 2024, reflecting higher earnings per share for investors.
- Return on Net Worth (RoNW): The RoNW has increased from 0.71% to 2.68%, indicating an increase in the company’s ability to generate returns on shareholder equity.
- Financial Position: Total assets have increased, suggesting potential business growth.
Sai Life Sciences IPO Financial Analysis
| Particular | As of 31 March 2022 | As of 31 March 2023 | As of 30 September 2024 |
| Revenue (₹ in millions) | 8,695.93 | 12,171.39 | 6,752.85 |
| Equity (₹ in millions) | 8,785.65 | 8,880.93 | 10,455.58 |
| Expenses (₹ in millions) | 8,880.46 | 12,286.97 | 6,560.92 |
| Profit and Loss After Tax (₹ in millions) | 62.26 | 99.89 | 280.12 |
| Diluted EPS only (₹) | 0.34 | 0.55 | 1.49 |
| Return on Net Worth (%) | 0.71 | 1.13 | 2.68 |
| NAV per Equity Share (₹) | 48.90 | 49.18 | 55.93 |
| Total Assets (in millions) | 21,642.30 | 21,866.48 | 24,767.80 |
| Total Liabilities (in millions) | 12,856.65 | 12,985.55 | 14,312.22 |
Sai Life Sciences Limited IPO Peer Comparison
Sai Life Sciences, Divi’s Laboratories, Suven Pharmaceuticals, and Syngene International demonstrate varying scales of market capitalization, profitability, and earnings potential, reflecting their diverse operational strengths and market positioning within the pharmaceutical and biotechnology sectors.
| Company | Net Profit (₹ in millions) | Face Value per Equity Share (₹) | P/E Ratio | EPS (Basic) (₹) | EPS (Diluted) (₹) | RoNW (%) | NAV (₹ in millions) |
| Sai Life Sciences Limited | 14,651.78 | 1 | NA | 4.57 | 4.53 | 8.50 | 53.83 |
| Divi’s Laboratories Limited | 78,450.00 | 2 | 103.04 | 60.27 | 60.27 | 11.79 | 511.21 |
| Suven Pharmaceuticals Limited | 10,513.54 | 1 | 109.37 | 11.80 | 11.80 | 14.64 | 94.04 |
| Syngene International Limited | 34,886.00 | 10 | 73.59 | 12.71 | 12.69 | 11.98 | 105.91 |
Sai Life Sciences Ltd IPO Objective
The main objective of Sai Life Sciences Limited is to partially or fully repay or prepay outstanding borrowings.
- Repayment/ prepayment, in part or whole, of all or certain outstanding borrowings availed by the company: The company intends to utilise INR 720 crores to repay or prepay borrowings, improving its debt-equity ratio, reducing interest costs, enhancing internal accruals for growth, and enabling future fundraising for business expansion.
- General corporate purposes: The company will deploy funds for general corporate purposes, including strategic initiatives, growth and expansion, brand building, purchasing equipment, covering ordinary business expenses, and other related purposes.
Sai Life Sciences IPO Risks And Challenges
Sai Life Sciences Limited’s risks include dependency on biotech funding, exposure to rigorous customer audits, and challenges meeting regulatory standards. Discontinuations, failure to meet expectations or contract terminations could adversely affect financial performance and reputation.
- The company’s revenue relies on biotechnology customers, whose funding is sensitive to market fluctuations. Although no significant impact from customer closures or budget reductions occurred recently, the company’s ongoing dependency on biotech funding presents financial risks.
- Customers subject the company to rigorous audits and quality standards. While no significant issues have arisen, failure to meet these standards in the future could harm the company’s reputation, lead to contract termination, and impact financial performance.
- The company recently added 31, 40, 56, and 27 new products. Despite significant R&D investment, challenges remain in meeting regulatory standards and customer expectations, with occasional customer discontinuations posing potential business and financial performance risks.
Sai Life Sciences Ltd IPO – Industry & Market Potential
The global pharmaceutical market, valued at USD 1,451 billion in 2023, is expected to grow to USD 1,956 billion by 2028, driven by factors like chronic diseases, the ageing population, and increased health consciousness, with a 6.2% CAGR.
The Indian CRDMO industry grew from USD 4.0 billion in 2018 to USD 7.3 billion in 2023, with a 12.6% CAGR. Driven by increased R&D outsourcing and technical advancements, it’s expected to reach USD 14.1 billion by 2028.
The global CRO industry grew from $40.1 billion in 2018 to $76.5 billion in 2023, with a 13.7% CAGR. It’s driven by outsourcing, technology, and global expertise and is projected to reach $126.4 billion by 2028.
Sai Life Sciences Limited IPO – Type of Offer
Sai Life Sciences Limited plans a fresh issue of shares, seeking INR 950 crores to augment its repay borrowings partially or fully and fund general corporate purposes. Additionally, the company proposes an offer to sell 3.81 crore existing shares worth INR 2,092.62 crores.
- Fresh Issue: The company will issue new shares to raise capital, aiming to collect INR 950 crores. The company intends to utilise the proceeds from the fresh issue to repay borrowings partially or fully and fund general corporate purposes.
- Offer for sale: Sai Life Sciences Limited is offering to sell 3.81 crore existing shares worth INR 2,092.62 crores. The following are the details of the existing shareholders who are also the promoters selling the shares:
| Name of the promoter selling shareholder | No. of shares offered |
| Sai Quest Syn Private Limited | 6,454,780 |
Sai Life Sciences IPO Offer Size
The offer size of Sai Life Sciences Limited is INR 3,042.62 crores, consisting of a fresh issue of 1.73 crore shares worth INR 950 crores and an offer to sell 3.81 crore existing shares worth INR 2,092.62 crores. The company aims to repay borrowings partially or fully and fund general corporate purposes.
Sai Life Sciences Limited IPO Allotment Structure
Sai Life Sciences Limited’s allocation will be as follows: 35% for Qualified Institutional Buyers (QIB), 15% for Non-Institutional Investors (NII), and 35% for Retail Individual Investors (RII) according to SEBI regulations.
● Qualified Institutional Buyers (QIB): As per SEBI regulations, 35% of the shares offered through the IPO will be reserved for Qualified Institutional Buyers. These include entities such as banks, mutual funds, and insurance companies.
● Non-Institutional Investors (NII): 15% of the shares will be reserved for Non-Institutional Investors. These typically include corporate bodies or individuals investing more than Rs.2 lakhs.
● Retail Individual Investors (RII): The remaining 35% of the shares will be allotted to Retail Individual Investors. These individual investors apply for shares with a total value of less than Rs.2 lakhs.
How to apply for Sai Life Sciences IPO?
To apply for the Sai Life Sciences Limited IPO through Alice Blue, follow these steps:
Open a Demat and Trading Account: If you don’t have one already, you must open a Demat and trading account with Alice Blue.
- Check for IPO Details: Once your account is active, you can check for the Sai Life Sciences Limited IPO details in the IPO section of the Alice Blue platform.
- Place the Bid: Enter the number of shares you wish to buy and place your bid within the IPO’s price band.
- Submit the Application: Confirm all your details and submit your application.
You can apply for the Sai Life Sciences Limited IPO at Alice Blue in just a few clicks!
Check Allotment Status: After the allotment process, you can check the allotment status to see if you have received any shares.
Please note that the allotment of shares is not guaranteed and will depend on the demand for the IPO.
How do you check Sai Life Sciences IPO Allotment Status?
Checking the allotment status of an IPO in Alice Blue is usually straightforward. Please follow these general steps:
- Log in to your Alice Blue Account: You can do this through the Alice Blue website or the trading app.
- Navigate to the Portfolio or IPO Section: This might differ based on the layout of Alice Blue’s platform, but generally, you can find the status of your IPO application under the ‘Portfolio’ or ‘IPO’ section.
- Find the IPO Allotment Status: Look for a sub-section called ‘IPO Allotment Status’ or something similar. This is where you can see the status of the IPOs you have applied for.
- Select the Sai Life Sciences Limited IPO: If you have applied for multiple IPOs, there might be a dropdown menu or a list where you can select the IPO you are interested in. Select the Sai Life Sciences Limited IPO.
- Check the Status: The status of your application should be displayed here. If the shares have been allocated to you, it would be mentioned here.
If you face any issues, we request you reach out to our customer support team at Alice Blue for detailed assistance.
Apart from Alice Blue, there are other ways to check the allotment status of the Sai Life Sciences Limited IPO:
● Registrar’s Website: Visit the website of KFin Technologies Limited, the registrar of the Sai Life Sciences Limited IPO. On the homepage, look for the ‘IPO Allotment Status’ option. You must enter your PAN, application, or Demat account number to check your allotment status. Click on the ‘Submit’ button to view your IPO allotment status.
● BSE NSE: You can also check the allotment status on the official websites of the Bombay Stock Exchange (BSE) National Stock Exchange (NSE). You would need your application number and PAN to check the status.
Please note that the allotment status will only be available after completing the allotment process, a few days after the IPO window closes.
Sai Life Sciences Ltd IPO Offer Registrar
The registrar for the Sai Life Sciences Limited IPO is KFin Technologies Limited. They are responsible for ensuring the IPO allotment and refund processes are carried out smoothly.
Contact information for the registrar:
KFin Technologies Limited Selenium,
Tower-B, Plot No. 31 and 32 Financial
District Nanakramguda, Serilingampally
Hyderabad 500 032 Telangana, India
Tel: +91 40 6716 2222
E-mail: [email protected]
Website: www.kfintech.com
Sai Life Sciences IPO – FAQs
1. What is the allotment date of the Sai Life Sciences IPO?
The allotment date of the Sai Life Sciences is December 16, 2024.
2. What is the price band of the Sai Life Sciences IPO?
The price band of the issue is INR 522-549 per share.
3. What is the size of the Sai Life Sciences IPO?
The offer size of Sai Life Sciences Limited is INR 3,042.62 crores, consisting of a fresh issue of 1.73 crore shares worth INR 950 crores and an offer to sell 3.81 crore existing shares worth INR 2,092.62 crores. The company aims to repay borrowings partially or fully and fund general corporate purposes.
4. What is the listing date of the Sai Life Sciences IPO?
The listing date of the Sai Life Sciences is December 18, 2024.
5. Where is the Sai Life Sciences IPO Getting Listed?
Sai Life Sciences is getting listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
6. What are the open and close dates of the Sai Life Sciences Limited IPO?
The open and close dates of the Sai Life Sciences Limited are December 11, 2024 and December 13, 2024, respectively.
7.How to apply for Sai Life Sciences Ltd IPO in Alice Blue?
To apply for the Sai Life Sciences Limited IPO through Alice Blue, open a Demat and Trading Account, check IPO details, place your bid within the price band, and submit your application. After allotment, check your status, noting that share allocation depends on demand.
8. Who are the Book Runners for the Sai Life Sciences IPO?
The Book Runners for Sai Life Sciences are Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited and Morgan Stanley India Company Private Limited.
